Multimodality Treatement in Patients with Clinical Stage IIIA NSCLC

임상적 IIIA병기 비소세포폐암의 다각적 치료의 효과

  • Lee, Yun Seun (Department of Internal Medicine, College of Medicine, Chungnam National University) ;
  • Jang, Pil Soon (Department of Internal Medicine, College of Medicine, Chungnam National University) ;
  • kang, Hyun Mo (Department of Internal Medicine, College of Medicine, Chungnam National University) ;
  • Lee, Jeung Eyun (Department of Internal Medicine, College of Medicine, Chungnam National University) ;
  • Kwon, Sun Jung (Department of Internal Medicine, College of Medicine, Chungnam National University) ;
  • An, Jin Yong (Department of Internal Medicine, College of Medicine, Chungnam National University) ;
  • Jung, Sung Soo (Department of Internal Medicine, College of Medicine, Chungnam National University) ;
  • Kim, Ju Ock (Department of Internal Medicine, College of Medicine, Chungnam National University) ;
  • Kim, Sun Young (Department of Internal Medicine, College of Medicine, Chungnam National University)
  • 이연선 (충남대학교 의과대학 내과학교실) ;
  • 장필순 (충남대학교 의과대학 내과학교실) ;
  • 강현모 (충남대학교 의과대학 내과학교실) ;
  • 이정은 (충남대학교 의과대학 내과학교실) ;
  • 권선중 (충남대학교 의과대학 내과학교실) ;
  • 안진영 (충남대학교 의과대학 내과학교실) ;
  • 정성수 (충남대학교 의과대학 내과학교실) ;
  • 김주옥 (충남대학교 의과대학 내과학교실) ;
  • 김선영 (충남대학교 의과대학 내과학교실)
  • Received : 2004.07.13
  • Accepted : 2004.10.13
  • Published : 2004.12.30

Abstract

Background : To find out effectiveness of multimodality treatments based on induction chemotherapy(CTx) in patients with clinical stage IIIA NSCLC Methods : From 1997 to 2002, 74 patients with clinical stage IIIA NSCLC underwent induction CTx at the hospital of Chungnam National University. Induction CTx included above two cycles of cisplatin-based regimens(ectoposide, gemcitabine, vinorelbine, or taxol) followed by tumor evaluation. In 30 complete resection group, additional 4500-5000cGy radiotherapy(RTx) was delivered in 15 patients with pathologic nodal metastasis. 29 out of 44 patients who were unresectable disease, refusal of operation, and incomplete resection were followed by 60-70Gy RTx in local treatment. Additional 1-3 cycle CTx were done in case of induction CTx responders in both local treatment groups. Results : Induction CTx response rate were 44.6%(complete remission 1.4% & partial response 43.2%) and there was no difference of response rate by regimens(p=0.506). After induction chemotherapy, only 33 out of resectable 55 ones(including initial resectable 37 patients) were performed by surgical treatment because of 13 refusal of surgery by themselves and 9 poor predicted reserve lung function. There were 30(40.5%) patients with complete resection, 2(2.6%) persons with incomplete resection, and 1(1.3%) person with open & closure. Response rate in 27 ones with chest RTx out of non-operation group was 4.8% CR and 11.9% PR. In complete resection group, relapse free interval was 13.6 months and 2 year recur rate was 52%. In non-complete resection(incomplete resection or non-operation) group, disease progression free interval was 11.2 months and 2 year disease progression rate was 66.7%. Median survival time of induction CTx 74 patients with IIIA NSCLC was 25.1months. When compared complete resection group with non-complete resection group, the median survival time was 31.7 and 23.4months(p=0.024) and the 2-year overall survival rate was 80% and 41%. In the complete resection group, adjuvant postoperative RTx subgroup significantly improved the 2-year local control rate(0% vs. 40%, p= 0.007) but did not significantly improve overall survival(32.2months vs. 34.9months, p=0.48). Conculusion : Induction CTx is a possible method in the multimodality treatments, especially followed by complete resection, but overall survival by any local treatment(surgical resection or RTx) was low. Additional studies should be needed to analysis data for appropriate patient selection, new chemotherapy regimens and the time when should RTx be initiated.

연구배경 : 비소세포폐암 중 IIIA병기는 같은 병기라도 다양한 임상적 경과를 밟고 어느 한가지 치료만으로는 치료 성적이 좋지 못하다. 이에 최근에는 다각적치료(항암, 화학치료, 방사선치료 및 수술적 치료)가 치료의 근간이 되고 있고 이에 대한 연구가 많이 시도되고 있으며 일부에서는 긍정적인 결과를 보고 하고 있다. 이에 저자들은 유도화학요법에 근간을 둔 다각적 치료의 효과를 살펴보고자 연구를 계획하였다. 방 법 : 1997.1월부터 2002.12월까지 충남대학교 병원에 내원하여 임상적으로 비소세포폐암 IIIA병기 진단을 받고 초치료로 유도화학치료를 시행받은 환자에 대하여 다각적 치료의 반응률, 재발율 및 생존기간등을 살펴보았다. 결 과 : 1) 유도화학요법은 74명에게서 시행되었고 반응률은 44.6%(완전관해 1.4% 및 부분반응 3.2%)였고, 고전적약(VPP)과 신약과의 반응률은 차이가 없었다(38.9%vs. 50%, p=0.506). 임파선의 반응률은 다발성 N2이상 병기로 수술적 치료에 어려움이 있다고 판단됐던 37명중 18명(54%)에서 단발성 N2이하로 병기하향을 보였고 이중 수술거부 6명과 폐기능문제 4명을 제외한 8명(21%)이 수술을 시행 받았다. 단발성 N2병기의 경우는 37명중 33명(89%)에게서 단발성 N2이하로 병기유지 내지 하향을 보였고 수술거부 7명과 폐기능문제 5명을 제외한 21명(56.7%)이 수술을 시행 받았다. 유도화학요법 후 다발성 N2였으나 수술적 절제가 가능하다고 판단됐던 4명의 경우에도 수술이 시행되어 전체 환자 중 수술적 치료는 33명(44.5%)에게서 시행되었으며, 완전절제는 30명(40.5%)이었고, 2명(2.6%)의 경우는 불완전 절제, 그리고 1명(1.3%)의 경우는 산소 포화도가 유지가 되지 않아 바로 봉합하였다. 2) 유도화학요법후 WHO기준 3이상의 호중구 감소증은 20명(25.7%)에서 발생하였고 이에 병발된 폐렴은 3명에게서 발생하였으나 이로 인한 사망은 없었다. 3) 수술적 절제가 불가능하여 방사선 치료를 시행하였던 27명의 반응률은 완전관해가 4.8%였고 부분반응은 11.9%였다. 4) 완전 절제되었던 군의 무병지속기간은 13.6개월이었고, 2년의 추적관찰기간 시점의 재발률은 52%였으며, 추가 방사선 치료군의 국소 재발율은 의미있게 적었다(0% vs. 40%, 0.02). 완전 절제되지 못하였거나 불완전 절제된 군의 무진행 질병기간은 11.2개월이었고, 2년의 추적관찰기간 시점의 병의 진행률은 66.7%였다. 5) 전체 대상환자의 중앙생존기간은 25.1개월이었고, 유도화학요법 후 수술 적으로 완전절제를 이루었던 군이 국소 치료로 방사선 치료를 시행하였던 군에 비하여 생존기간이 유의하게 길었지만(31.7개월 vs. 26.1개월, p=0.04), 완전절제 된 군의 추가 방사선 치료에 따른 생존 이득은 없었다. (34.9개월 vs. 32.2개월, p=0.48) 결 론 : 이상의 결과로 임상적 IIIA병기 비소세포폐암의 치료로 다각적 치료시 유도화학요법 후 가능하다며 수술적으로 완전절제를 이루는 것이 가장 좋은 치료라 생각된다. 하지만 전체적인 생존율은 그다지 높지 못하여 유도화학요법시 추가적인 방사선 치료, 수술 후 보조적 항암화학요법, 그리고 생물학적 치료제 등에 대한 보다 많은 3상 연구가 필요하리라 생각된다.

Keywords

References

  1. 사망원인 통계연보; 인구동태 신고에 의한 집계. 통계청 2002
  2. 한국중앙암등록 사업 연례 보고서. 2001
  3. Rosell R, Gomez-Codina J, Camps C, Javier Sanchez J, Maestre J, Padilla J, et al. Preresectional chemothrapy in stage ⅢA non-small-cell lung-cancer: a 7-year assessment of a randomized controlled trial. Lung cancer 1999;26:7-14
  4. Roth JA, Atkinson EN, Fossella F, Komaki R, Bernadette Ryan M, Putnam. JB Jr, et al. Long-term. follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage ⅢAnon-small-cell lung cancer. Lung Cancer. 1998;21(1):1-6
  5. Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: Interim, analysis. Ann Thorac Surg 1992;53:992-8
  6. Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, et al. Properative chiemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), Ⅱ, and Ⅲa non-small-cell lung cancer. J Clin Oncol. 2002;20(1):247-53
  7. Robinson LA, Wagner H Jr, Ruckdeschel JC; American Colleage of chest physians. Treatment of stage ⅢA non-small cell lune cancer. Chest 2003; 123:202S-220S
  8. Cardenal F, Lopez-Cabrerizo MP, Anton A, Alberola V, Massuti B, Carrato A, et al. Randomized phase Ⅲ study of gemcitabine-cisplatin versus etoposide cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999;17(1):12-8
  9. Crino L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase Ⅲ study of the Italian Lung Cancer Rroject. J Clin Oncol. 1999 17(11):3522-30
  10. Van Zandwijk N, Smit EF, Kramer GW, Schramel F, Gans S, Festen J, et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage ⅢA N2 non-small-cell lung cancer: a phase Ⅱ study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol. 2000;18(14):2658-64
  11. Van Kooten M, Rosenberg M, Orlando M, Morero J, Vilanova M, Rojas O, et al. Neoadjuvant chemo-therapy with gemcitabine and cisplatin in stage ⅢA/B non-small cell lung cancer. Invest New Drugs 2002;20(4):439-46
  12. Yang CH, Tsai CM, Wang LS, Lee YC, Chang CJ, Lui LT, et al. Gemcitabine and cisplatin in a multi-modality treatment for locally advanced non-small cell lung cancer. Br J Cancer. 2002;86(2):190-5
  13. Arriagada R, Le Pechoux C, Pignon JP. Resected non-small cell lung cancer: need for adjuvant lymph node treatment? From hope to reality. Lung Cancer. 2003:42 Suppl 1:S57-64
  14. Rescigno J. Use of postoperative radiotherapy for node-positive non-small-cell lung cancer. Clin Lung Cancer. 2002;4(1):35-44
  15. PORT Meta-analysis Trialists Group; Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998;352:257-63
  16. Taylor NA, Liao ZX, Cox JD, Stevens C, Roth J, Walsh G, et al. Equivalent outcome of patients withclinical Stage ⅢA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys. 2004;58(1):204-12
  17. Dillman RO, Hemdon J, Seagren SL, Eaton WL Jr, Green MR Improved survival in stage Ⅲ non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88(17):1210-5
  18. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first an-alysis of a randomized trial in 353 patients. J Natl cancer Inst 1991;83(6):417-423
  19. Perez CA, Pajak TF, Rubin P, Simpson JR, Mohiuddin M, Brady LW, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcincoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy On-cology Group. Cancer 1987;59:1874-81
  20. Marino P, Rreatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages Ⅲa and Ⅲb nonsmall cell lung cancer. A meta-analysis. Cancer 1995;76:593-601
  21. Keller SM, Adak S, Wagner H Herakovic A, Komaki R, Brooks BJ, et al. A randomized trial of posto-perative adjuvant therapy in patients with com-pletely resected stage Ⅱ or ⅢA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000;343:1217-22
  22. Scagliotti GV, Fossati R, Torri V, Crino L, Giaccone G, Silvano G, et al. Randomized study of adjuvant chemotherapy for completely resected stage Ⅰ, Ⅱ, or ⅢA non-small-cell Lung cancer. J Natl Cancer Inst. 2003 ;95(19):1453-61
  23. Arriagada B, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with com-pletely resected non-small-cell lung cancer. N Engl J Med 2004;350: 351-60
  24. Sparwasser T, Kodi ES, Vabulas RM, Heee K, Lipford GB, Ellwart JW, et al. Bacterial DNA and immuno-stimlatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998;28:2045-54
  25. Hartmaim G, Weiner GJ, Kriee AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 1999; 96:9305-10